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Abstract
Granular/fuzzy astrocytes (GFAs), a subtype of “aging-related tau astrogliopathy,” 
are noted in cases bearing various neurodegenerative diseases. However, the patho-
genic significance of GFAs remains unclear. We immunohistochemically examined 
the frontal cortex, caudate nucleus, putamen and amygdala in 105 cases composed 
of argyrophilic grain disease cases (AGD, N  =  26), and progressive supranuclear 
palsy (PSP, N  =  10), Alzheimer’s disease (AD, N  =  20) and primary age-related 
tauopathy cases (PART, N  =  18) lacking AGD, as well as 31 cases bearing other 
various neurodegenerative diseases to clarify (i) the distribution patterns of GFAs 
in AGD, and PSP, AD and PART lacking AGD, (ii) the impacts of major patho-
logical factors and age on GFA formation and (iii) immunohistochemical features 
useful to understand the formation process of GFAs. In AGD cases, GFAs consist-
ently occurred in the amygdala (100%), followed by the putamen (69.2%) and caudate 
nucleus and frontal cortex (57.7%, respectively). In PSP cases without AGD, 
GFAs  were almost consistently noted in  all regions examined  (90–100%). In AD 
cases without AGD, GFAs were less frequent, developing preferably in the putamen 
(35.0%) and caudate nucleus (30.0%). PART cases without AGD had GFAs most 
frequently in the amygdala (35.3%), being more similar to AGD than to AD cases. 
Ordered logistic regression analyses using all cases demonstrated that the strongest 
independent factor of GFA formation in the frontal cortex and striatum was the 
diagnosis of PSP, while that in the amygdala was AGD. The age was not signifi-
cantly associated with GFA formation in any region. In GFAs in AGD cases, phos-
phorylation and conformational change of tau, Gallyas-positive glial threads indis-
tinguishable from those in tufted astrocytes, and the activation of autophagy occurred 
sequentially. Given these findings, AGD, PSP, AD and PART cases may show distinct 
distributions of GFAs, which may provide clues to predict the underlying processes 
of primary tauopathies.
INTRODUCTION
Currently, the pathological diagnosis of various tauopathies 
is based on the presence of disease-specific neuronal and 
glial inclusions in which phosphorylated tau protein is abnor-
mally aggregated, as well as their anatomical distribution. 
Neurofibrillary tangles (NFTs) are the most common non-
disease-specific tau-positive lesions, and historically, several 
studies have attempted to define several diseases by the 
anatomical distributions of NFTs alone visualized by early 
silver impregnation methods. Thereafter, argyrophilic astro-
cytic lesions demonstrated by a sensitive silver stain, the 
Gallyas method, that is, tufted astrocytes (TAs) (35,57,58,77) 
and astrocytic plaques (16,35), were found to have diagnostic 
value in progressive supranuclear palsy (PSP) and cortico-
basal degeneration (CBD). The Gallyas method also dem-
onstrated the thorn-shaped astrocytes that are found in cases 
having various pathological conditions (26). Subsequently, 
the accumulation of phosphorylated tau in these astrocytic 
lesions was reported (16,26,57).
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Besides thorn-shaped astrocytes, another morphological 
subtype of tau-positive non-disease-specific astrocytic lesions 
has been reported. The astrocytic lesions have a small amount 
of tau accumulation in the perinuclear regions of astrocytes, 
as well as fine or fuzzy granular tau accumulation in astro-
cytic processes. Botez et al first described this subtype of 
astrocytic lesions in the amygdala in brains with argyrophilic 
grain disease (AGD) and called them “bush-like astrocytes” 
(4). They also noticed that these astrocytic lesions were not 
stained by the Gallyas method. Thereafter, morphologically 
and immunohistochemically similar tau-positive astrocytic 
lesions were also reported using different terms, for example, 
diffuse granular tau immunoreactivity in astrocytic processes 
(42), diffuse granular tau immunopositivity along astrocytic 
processes (41), fine granular tau immunoreactivity in astro-
cytic processes (17), astrocytes with finely tau immunoreactive 
processes (76), TA-like astrocytic lesions (27) and granular-
shaped astrocytes (80). In a recently proposed classification 
of tau-positive astrocytic lesions, these tau-positive astrocytic 
lesions were called “granular/fuzzy astrocytes (GFAs)” as a 
subtype of “aging-related tau astrogliopathy (ARTAG)” (38).
GFAs preferably occur in the gray matter, that is, the 
cerebral cortex and nuclei rather than the white matter 
(37,38). GFAs are basically Gallyas-negative, although accu-
mulated tau only in the cytoplasm of astrocytes can rarely 
show weak argyrophilia (38). GFAs can be found in elderly 
cases having heterogeneous clinical and pathological bases 
(17,27,41,42), including PSP (27,44,80), Alzheimer’s disease 
(AD) (44), primary age-related tauopathy (PART) (44), CBD 
(44), Pick’s disease (44) and chronic traumatic encephalopathy 
(18). It is not always easy to evaluate the effect of each 
pathology on GFA formation because several tauopathies 
often coexist in a single case. Especially, given that AGD 
increases in frequency with age (9) and might be associated 
with the development of GFAs (4), the potential effect of 
AGD on the frequency of GFAs in other tauopathies needs 
to be carefully evaluated. However, although only a few 
previous studies have examined the relationship between 
various tauopathies and ARTAG (ie, thorn-shaped astrocytes 
and GFAs) (43,44), as far as we know, the frequency and 
distribution of GFAs by specific anatomical regions in 
pathological conditions common in the elderly, that is, AGD, 
PSP without AGD, AD without AGD or PART without 
AGD, have not been examined.
The aims of the study described here were to examine 
(i) the frequency and distribution of GFAs in AGD cases, 
as well as PSP, AD and PART cases lacking AGD, respec-
tively, (ii) the impacts of major pathological factors and 
the age on GFA formation in regions in which GFAs pref-
erably occur and (iii) immunohistochemical findings useful 
to understand the formation process of GFAs. To address 
these issues, we first semiquantitatively examined GFAs, as 
well as TAs, which are potentially related to GFA forma-
tion (27), in the frontal cortex, caudate nucleus, putamen 
and amygdala in AGD, PSP, AD and PART cases, as well 
as cases of various other degenerative diseases. Then, after 
performing univariate and multivariate analyses to assess 
the effects of factors on the development of GFAs by region 
in all cases, we examined the immunohistochemical features 
of GFAs in AGD cases using phosphorylation- or confor-
mational change-specific anti-tau, anti-ubiquitin and anti-p62 
antibodies as well as the Gallyas method. In this paper, 
we demonstrate that GFAs may occur with disease-specific 
distribution patterns in cases of AGD, PSP without AGD, 
AD without AGD and PART without AGD, respectively, 
and that age may not be always associated with GFA for-
mation. In addition, we demonstrate that the increase of 
immunoreactivities of phosphorylation- and conformation-
dependent anti-tau antibodies in GFAs, the occurrence of 
Gallyas-positive glial threads in GFAs and the activation 
of autophagy may occur sequentially in AGD cases.
MATERIALS AND METHODS
Subjects
A total of 1125 autopsy cases were registered in the data-
base at the Department of Neuropsychiatry, Okayama 
University Graduate School of Medicine, Dentistry and 
Pharmaceutical Sciences as of the end of December 2017. 
All cases died in psychiatric hospitals or neurological depart-
ments of general hospitals. We first selected 202 cases that 
were recently assessed using modern standardized methods 
including a panel of immunohistochemistry, modified 
Bielschowsky silver stain and Gallyas-Braak silver stain from 
2001 to 2017 for the selection of AGD, PSP, AD and 
PART cases. AGD cases (N  =  26) that lacked any other 
primary tauopathies except for PART [ie, AD, PSP, CBD, 
globular glial tauopathy (GGT), diffuse NFTs with calcifica-
tion (DNTC), Pick’s disease and frontotemporal lobar degen-
eration with tau gene mutation (FTLD-MAPT)] were selected. 
Likewise, PSP (N  =  10) cases that lacked any other primary 
tauopathies except for PART were selected. AD (N  =  20) 
cases without any other tauopathies were then selected. Definite 
PART cases without any other degenerative disease [N = 5; 
Braak & Braak stage (Braak stage) I–IV, Thal phase 0] were 
also selected from the 202 cases.
Then, to evaluate the effect of age and common patho-
logical factors (ie, Braak stage, Thal phase, the presence of 
Lewy bodies and TDP-43 pathology) on the development 
of GFAs, 19 cases of other various tauopathies, that is, 
CBD (N  =  7), GGT (N  =  2), DNTC (N  =  5), Pick’s 
disease (N = 3), FTLD-MAPT (N = 1) and postencephalitic 
parkinsonism (N  =  1), as well as 25 non-tauopathy cases 
lacking any other tauopathies except for PART, that is, 
myotonic dystrophy (N = 4), multiple system atrophy (MSA, 
N  =  6), frontotemporal lobar degeneration with TDP-43-
positive inclusions (FTLD-TDP, N = 3), amyotrophic lateral 
sclerosis with TDP-43-positive inclusions (ALS-TDP, N = 4), 
FTLD with fused in sarcoma (FUS)-positive inclusions 
(FTLD-FUS, N  =  3), Huntington’s disease (N  =  1) and 
dentatorubral-pallidoluysian atrophy (DRPLA, N = 4), were 
selected from our 1125 cases.
Among the 25 non-tauopathy cases, 13 cases also had 
PART: nine had definite PART (Braak stage I–IV, Thal 
phase 0), and four had possible PART (Braak stage I–IV, 
and Thal phases 1–2). Therefore, we made a PART group 
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(N  =  18) by combining these additional 13 PART cases 
and the first five definite PART cases without any other 
degenerative diseases (Supporting File S1).
The demographic data of  a total of  the 105 cases that 
we eventually examined in the present study are shown 
in Table  1. In this study, except for AGD and CBD cases, 
we selected only cases that lacked argyrophilic grains in 
any anatomical region. Because all of  our CBD cases 
had various degrees of  AGD, they were exceptionally 
included in this study despite the coexistence of  AGD. 
Regarding PSP pathology, several previous studies includ-
ing ours suggested that AGD cases often had small numbers 
of  NFTs and TAs in the basal ganglia and brain stem 
nuclei, distribution of  which is reminiscent of  that in PSP 
cases (27,64). While TAs are considered to be specific to 
PSP, whether all TAs observed in cases of  other diseases 
mean an early change of  PSP remains unclear. Therefore, 
in the present study, even when cases had a few Gallyas- 
or AT8-positive TAs, they were not diagnosed as PSP 
when lacking NFTs that met the pathological criteria of 
PSP (25). For example, when an AGD case had a few 
AT8-positive TAs but lacked sufficient NFTs that fit the 
pathological criteria of  PSP, the case was classified into 
an AGD group.
Autopsies were carried out after informed consent was 
obtained from family members, and all experiments in this 
study were approved by the ethical committees of the 
Okayama University Graduate School of Medicine, Dentistry 
and Pharmaceutical Sciences, the National Hospital 
Organization Minami-Okayama Medical Center, Zikei 
Institute of Psychiatry and the Tokyo Metropolitan Institute 
of Medical Science.
The criteria of  each pathological diagnostic category 
were as follows: AGD was diagnosed based on Gallyas-
positive grains in the limbic system with and without the 
temporal cortex (7) and the absence of  any other primary 
tauopathies except for PART (13) [ie, NFTs with Braak 
stage I–IV (6,8) and no or minimal Aβ deposits with 
Thal phase 0–2 (69)]. The diagnosis of  PSP was based 
on the presence of  both Gallyas-positive TAs and AT8-
positive NFTs whose quantity and distribution met the 
pathological criteria of  either typical or atypical PSP (25). 
The AD group was composed of  cases having intermedi-
ate or high level AD pathology (Braak stage V–VI, Thal 
phase 3–5) (52). Cases of  CBD met the pathological cri-
teria and had Gallyas-positive AT8-positive astrocytic 
plaques in the striatum and frontal cortex (15). Cases of 
GGT (N  =  2) had numerous 4-repeat (4R) tau-positive 
3-repeat (3R) tau-negative globular glial inclusions that 
correspond to type I (N  =  1) and type II (N  =  1) his-
tologies (1). DNTC was diagnosed based on severe NFTs 
(Braak stage VI), the absence of  or minimal Aβ deposits 
(ie, Thal phase 0–1), Fahr-type calcification and circum-
scribed temporal lobe atrophy (31,36,66,78). Pick’s disease 
was defined by the presence of  3R tau-positive 4R tau-
negative Pick bodies (53,79). Previously reported cases of 
frontotemporal lobar degeneration due to P301L tau muta-
tion (50) and postencephalitic parkinsonism (22) were also 
included. Because, the case of  postencephalitic 
parkinsonism showed distinct clinical and pathological 
findings (30), it was not included in the AD group although 
it had severe NFTs and Aβ deposits (Braak stage V, Thal 
phase 4). MSA was diagnosed based on Gallyas-positive 
α-synuclein-positive Papp–Lantos inclusions and tissue 
degeneration with a distinctive distribution (61,74). 
Diagnoses of  FTLD-TDP (2,12,47,56) and ALS-TDP were 
based on TDP-43 pathology and neuronal loss with a 
distinct distribution and the absence of  other primary 
neurodegenerative diseases. FTLD-FUS was composed of 
two cases of  basophilic inclusion body disease and one 
ALS case with the FUS mutation (12,54,55). The diagnoses 
of  DRPLA and Huntington’s disease were pathologically 
and genetically confirmed. Myotonic dystrophy cases had 
a diagnosis of  DM1 by genetic and/or clinical criteria 
(21,71).
Conventional neuropathological examination 
and immunohistochemistry
A standardized neuropathological evaluation was done on 
all subjects. Brain tissue samples were fixed post-mortem 
with 10% of formaldehyde and embedded in paraffin. Ten-
µm-thick sections from the frontal, temporal, parietal, occipi-
tal, insular and cingulate cortices, hippocampus, amygdala, 
basal ganglia, midbrain, pons, medulla oblongata and cer-
ebellum in the left hemisphere were prepared. For the stand-
ardized neuropathological assessment, sections were stained 
with hematoxylin-eosin and Klüver-Barrera stains, and 
selected regions stained with modified Bielschowsky silver 
and Gallyas methods.
Then, formalin-fixed paraffin sections were cut at six μm 
thickness from selected regions from all cases for the stand-
ard immunohistochemical evaluation of representative neu-
rodegenerative changes. Deparaffinized sections were 
incubated with 1% of H2O2 in methanol for 30  minutes to 
eliminate endogenous peroxidase activity, and washed in 
phosphate-buffered saline (PBS, pH 7.4). After blocking with 
10% of normal serum, sections were incubated overnight 
at 4°C with primary antibodies (Table  2). When using anti-
tau, anti-ubiquitin, anti-p62, anti-α-synuclein and anti-
TDP-43 antibodies, sections were autoclaved for 10  minutes 
in 10  mM of sodium citrate buffer at 121°C for antigen 
retrieval. When using 12B2, RD4, RD3 and T22, sections 
were autoclaved for 10  minutes in 10  mM of sodium citrate 
buffer at 121°C and treated with 70% of formic acid for 
10  minutes. After three 5-min washes in PBS, sections were 
incubated in biotinylated secondary antibody for 30 minutes, 
and then, in avidin-biotinylated horseradish peroxidase com-
plex (ABC Elite kit, Vector, Burlingame, CA, USA) for 
60 minutes. After three 5-min washes in PBS, the peroxidase 
labeling was visualized with 3,3’-diaminobenzidine (DAB) 
as the chromogen. Sections were lightly counterstained with 
hematoxylin.
AGD was diagnosed based on the presence of Gallyas-, 
AT8- and RD4-positive argyrophilic grains, and the distri-
bution was assessed using sections stained with the Gallyas 
method and the staging system reported by Saito et al (63). 
Other major degenerative changes, that is, NFTs (AT8, 
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Gallyas method) (6), Aβ deposits (12B2) (69), neuritic plaques 
(modified Bielschowsky silver method) (51), Lewy bodies 
(psyn#64) (49,75), TAs (Gallyas method, AT8, RD4) (1), 
astrocytic plaques (Gallyas method, AT8, RD4) (1), Pick 
bodies (AT8, RD3) (28), TDP-43 accumulation (pS409/410-
2) (10-12,33,34,47), globular glial inclusions (Gallyas method, 
AT8, RD4) (1,40,62) and FUS-positive pathology 
(HPA008784) (12,54,55) were also evaluated in all subjects 
using established criteria, respectively.
Semiquantitative assessment of GFAs and TAs
It was originally reported that GFAs were frequently found 
in the amygdala in AGD cases (4). Our previous study revealed 
that GFAs may be also frequent in the frontal cortex and 
striatum in AGD and PSP cases (27). In addition, it was 
reported that these regions may be potentially significant sites 
to understand the progression pattern of GFAs (44). Therefore, 
in the present study, we semiquantitatively evaluated the den-
sity of GFAs in the superior frontal gyrus, caudate nucleus, 
putamen and amygdala in all subjects using the staging system: 
stage 0, no lesion; stage 1, one or more lesions in the ana-
tomical region but less than one lesion per  ×  200 visual 
field; stage 2, one lesion per  ×  200 visual field; stage 3, 2 
to 10 lesions per  ×  200 visual field; stage 4, over 11 lesions 
per × 200 visual field. The grades were determined separately 
by two investigators (TM and OY) who did not know whether 
the case had any pathological data. If there was a discrepancy 
between the results, the two researchers reviewed the tissues 
and decided the final grade by discussion.
In our previous study, some AGD cases had a few astro-
cytic lesions that bore both tau-positive granular components 
like GFAs and Gallyas-positive glial threads like TAs (27). 
In PSP cases, TAs were reported to preferentially develop 
in the frontal cortex and striatum (3,24,29). Therefore, in 
this study, to examine the relationship between GFAs and 
TAs, TAs were additionally evaluated in the superior frontal 
gyrus, caudate nucleus, putamen and amygdala in all cases 
on AT8- and Gallyas-stained sections, respectively, using 
the staging system for GFAs.
To secure the reproducibility of results, we regarded tau-
positive astrocytic lesions as GFAs only when the lesions 
had the typical morphological features of GFAs (Figure 1A–
G) originally reported in AGD cases (4) and shown in the 
consensus paper on ARTAG (38). In addition, because it 
is difficult to sharply distinguish “GFAs with Gallyas-positive 
glial threads” from “Gallyas-positive TAs” on Gallyas-stained 
sections, we counted astrocytic lesions having Gallyas-stained 
glial threads as TAs irrespective of the quantity of threads.
Double immunohistochemistry and double 
staining of AT8 immunohistochemistry and 
Gallyas method
To examine whether GFAs occur in association with Aβ 
deposits, double immunostaining with AT8 and 12B2 was 
done in all cases that had Aβ deposits in the frontal cortex, 
striatum and/or amygdala. Primary antibody labeling in the 
first cycle (AT8) was detected in the same way as single 
staining using the DAB reaction. Then, primary antibody 
labeling in the second cycle (12B2) was also detected in 
the same way as single staining, and the reaction was visu-
alized with Vector Blue Alkaline Phosphatase Substrate 
(Vector Laboratories, Inc.) as the chromogen.
Table 2. Antibodies used in this study
Antibody Species/type Dilution Epitope Source
AT8 Mouse/monoclonal 1:1000 Tau phosphorylated at Ser 202 Innogenetics
AT100 Mouse/monoclonal 1:500 Tau phosphorylated at Ser 212 and Thr 214 Innogenetics
AT180 Mouse/monoclonal 1:500 Tau phosphorylated at Thr 231 Innogenetics
AT270 Mouse/monoclonal 1:500 Tau phosphorylated at Thr 181 Innogenetics
PHF-1 Mouse/monoclonal 1:250 Tau phosphorylated at Ser 396 and Ser 404 (20)
Alz-50 Mouse/monoclonal 1:250 Tau epitope at aa 5-15 (5)
MC-1 Mouse/monoclonal 1:250 Conformation-dependent tau epitope within aa 312-322 (32)
T46 Mouse/monoclonal 1:500 Phosphorylation independent epitope in aa 404-441 of human tau Invitrogen
T22 Rabbit/polyclonal 1:500 Tau oligomer (46)
RD3 Mouse/monoclonal 1:2000 3 repeat tau-specific anti-tau antibody Merck Millipore (67)
RD4 Mouse/monoclonal 1:100 4 repeat tau-specific anti-tau antibody Merck Millipore (67)
Anti-4R tau Rabbit/polyclonal 1:2000 4 repeat tau-specific anti-tau antibody Cosmo Bio
MAB1510 Mouse/monoclonal 1:500 Ubiquitin Merck Millipore
p62-N Guinea pig/polyclonal 1:200 N-terminus of p62 protein Progen Biotechnik
p62-C Guinea pig/polyclonal 1:500 C-terminus of p62 protein Progen Biotechnik
12B2 Mouse/monoclonal 1:100 Aβ(11–28) IBL
psyn#64 Mouse/monoclonal 1:5000 Phosphorylated α-synuclein Wako
pS409/410-2 Rabbit/polyclonal 1:5000 Phosphorylated TDP-43 Cosmo Bio
HPA008784 Rabbit/polyclonal 1:200 FUS Sigma-Aldrich
SMI31 Mouse/monoclonal 1:5000 Phosphorylated neurofilament Sternberger
GFAP Rabbit/polyclonal 1:100 Glial fibrillary acidic protein Dako
CD68 Mouse/monoclonal 1:500 CD68 Dako
Iba1 Rabbit/polyclonal 1:1000 C-terminus of Iba1 Wako
3F4 Mouse/monoclonal 1:1000 Prion protein Covance
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Double staining using the Gallyas method and AT8 immu-
nohistochemistry was also done in representative AGD and 
PSP cases to examine whether GFAs actually have TA-like 
Gallyas-positive glial threads. Sections were first stained by 
the Gallyas method, followed by immunostaining with AT8. 
The peroxidase labeling was visualized with Vector Red 
Alkaline Phosphatase Substrate (Vector Laboratories, Inc.) 
as the chromogen. Sections were lightly counterstained with 
hematoxylin.
Confocal laser scanning microscopy
Double-labeling immunofluorescence was performed with 
the combination of  phosphorylation-dependent anti-tau 
antibody (AT8, mouse, monoclonal, 1:500) and anti-4R 
tau antibody (anti-4R tau, rabbit, polyclonal, 1:300, Cosmo 
Bio Co., Tokyo, Japan), and the combination of  phos-
phorylation-dependent anti-tau antibody (AT8, mouse, 
monoclonal, 1:500) and anti-p62-C antibody (p62-C, guinea 
pig, polyclonal, 1:200, Progen, Heidelberg, Germany). 
Sections from the frontal cortex and caudate nucleus in 
representative AGD and PSP cases having TAs and GFAs 
were autoclaved for 10  minutes in 10  mM of  sodium 
citrate buffer at 120°C. Following washing in PBS, non-
specific antibody binding was blocked with a 5% of  skim-
milk buffer, and sections were incubated overnight with 
a mixture of  the two primary antibodies at 4°C. After 
washing in PBS, sections were incubated for 1  h at room 
temperature with a mixture of  two fluorescence-labeled 
secondary antibodies as follows: Alexa Fluor 488 goat 
anti-mouse IgG (1:200, Thermo Fisher Scientific, Waltham, 
MA), Alexa Fluor 594 goat anti-rabbit IgG (1:200, Thermo 
Fisher Scientific) or Alexa Fluor 647 goat anti-guinea pig 
IgG (1:200, Thermo Fisher Scientific). The specificity of 
fluorescent staining was confirmed by omission of  the 
primary antibody. To quench autofluorescence (lipofuscin), 
sections were incubated in 0.1% of  Sudan Black B for 
10  minutes at room temperature and washed with 0.5% 
of  Tx-PBS for 30 minutes. Sections were coverslipped with 
FluoromountTM (Diagnostic BioSystems, Pleasanton, CA). 
Images were collected using a confocal microscope LSM780 
(Carl Zeiss, Jena, Germany) in the Central Research 
Laboratory of  Okayama University Medical School. Alexa 
Fluor 488, Alexa Fluor 594 or Alexa Fluor 647 was excited 
with 488, 594 or 633 nm laser beams and observed through 
493–560 or 493–630, 595–712 or 638–747  nm emission 
prism windows, respectively.
Tau immunoblotting
Frozen brain tissue from the caudate nucleus and puta-
men of  the right hemisphere in two AGD and two PSP 
Figure 1. GFAs (A–H) and TAs (I–O) in AGD cases. GFAs are labeled 
with various anti-tau antibodies, that is, AT8 (A), AT100 (B), AT180 (C), 
Alz-50 (D), MC-1 (E), PHF-1 (F) and RD4 (G). TAs are also immunostained 
with AT8 (I), AT100 (J), Alz-50 (K), PHF-1 (L), T22 (M) and RD4 (N). GFAs 
and TAs are also visualized with p62-C (H, O). (A, E, F) The caudate 
nucleus, (B–D, G, I–O) frontal cortex, (H) putamen. All scale 
bars = 30 μm. 
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cases was available. In addition, frozen tissue from the 
frontal or temporal cortex in one PSP case, one CBD 
case and one AD case was examined as disease controls. 
These samples were used for Western blotting according 
to methods described previously (14,48). Brain samples 
(0.5  g) from patients were individually homogenized in 
10  mL of  homogenization buffer (HB: 10  mM Tris-HCl, 
pH 7.5, containing 0.8  M of  NaCl, 1  mM of  EGTA and 
10% sucrose). Sarkosyl was added to the lysates (final 
concentration: 2%), which were then incubated for 30 min-
utes at 37°C and centrifuged at 20  000  g for 10  minutes 
at 25°C. The supernatant was divided into tubes (each 
1.3  mL) and centrifuged at 100  000  g for 20  minutes at 
25°C. The pellets were further washed with sterile saline 
(0.5 mL/tube) and centrifuged at 100 000 g for 20 minutes. 
The resulting pellets were used as the sarkosyl-insoluble 
fraction (ppt). The sarkosyl-ppt was sonicated in 50  μL 
(/tube) of  30  mM Tris-HCl (pH 7.5) and solubilized in 
2  ×  sample buffer. Samples were run on gradient 4–20% 
polyacrylamide gels and electrophoretically transferred to 
PVDF membranes. Residual protein-binding sites were 
blocked by incubation with 3% of  gelatin (Wako) for 
10  minutes at 37°C, followed by overnight incubation at 
room temperature with primary anti-tau antibodies [T46, 
mouse, monoclonal, 1:2000. pS396, rabbit, monoclonal, 
1:2000 (23,68)]. The membrane was incubated for 1  h at 
room temperature with anti-mouse IgG (BA-2000, Vector 
Lab) or anti-rabbit IgG (BA-2000, Vector Lab), then incu-
bated for 30  minutes with avidin-horseradish peroxidase 
(Vector Lab), and the reaction product was visualized by 
using 0.1% of  DAB and 0.2  mg/mL of  NiCl2 as the 
chromogen.
Statistical analysis
The Mann–Whitney U test and Fisher’s exact test were 
used to compare the variables between two groups. When 
comparing the variables between three groups, Kruskal–
Wallis and Steel–Dwass tests were used. Spearman rank 
order correlation analysis was applied for univariate cor-
relations between two variables. To assess the effects of 
predictor variables on the formation of  GFAs, we con-
structed a multivariate ordered logistic regression model. 
The stages of  GFAs (stages 0 to 4) were categorized into 
three levels (stage 0, stage 1 and stages 2 to 4) by com-
bining categories in which the number of  cases was small, 
and the data were submitted as the dependent variable 
in the model. Independent variables tested for their asso-
ciation with the dependent variable consisted of  the age 
at death, Braak stage (stages 0 to 6), Thal phase (phases 
0 to 5), PSP (presence or absence) and AGD (presence 
or absence). Because univariate analyses demonstrated the 
possibility that clinical and pathological factors may have 
different effects on GFA formation by anatomical region, 
the multivariate analysis was carried out after stratification 
by anatomical region (ie, the frontal cortex, caudate nucleus, 
putamen and amygdala). Odds ratios (ORs) and 95% 
confidence intervals (CIs) were calculated after controlling 
simultaneously for potential confounders. A P-value < 0.01 
was accepted as significant. Statistical analysis was per-
formed using Bell Curve for Excel 2.15 (Social Survey 
Research Information Co., Ltd., Tokyo, Japan).
RESULTS
Morphological and immunohistochemical 
features of GFAs in all subjects
All the AGD cases had GFAs in at least one region 
examined (Figure  1A–G). GFAs were composed of  small 
tau-positive granules that were scattered around astrocytic 
nuclei or often radially arranged around the nuclei, and 
often in contact with vessel walls. These lesions were 
labeled with a series of  anti-tau antibodies except for 
RD3. Some GFAs were also p62-positive (Figure  1H). In 
AGD cases, the immunoreactive pattern of  TAs was similar 
to that of  GFAs (Figure  1I–O); however, no GFA having 
small argyrophilic granules was noted on Gallyas-stained 
sections. All PSP cases also had both GFAs and TAs in 
which immunoreactivity and morphological features were 
similar to those in AGD cases, respectively (Figure 2A–E). 
In the frontal cortex in AGD and PSP cases, GFAs tended 
to be distributed in the ridge of  the convolution rather 
than the depth of  the sulci, especially when the number 
of  lesions was small. Nine of  20 AD cases had a small 
number of  GFAs in at least one region (Figure  2F–J). 
Some GFAs in AD cases were observed to be spatially 
associated with a few short thick dystrophic neurites that 
may have originated from neurons (Figure  2G, an arrow). 
Even in AD cases, the overlap between GFAs and Aβ 
deposits was rare (Figure  2F–J). Seven of  all 18 PART 
cases had GFAs at least in one region examined 
(Figure  3A–D).
Of  seven CBD cases, one had a small number of  GFAs 
in all regions examined (Figure  2K,L), while all CBD 
cases had many unclassifiable astrocytic lesions reminiscent 
of  classic astrocytic plaques in which granular, oval or 
rod-like tau accumulations tended to be distributed in the 
peripheral region (Figure  2M,N) in addition to classic 
astrocytic plaques (Figure  2O). One case of  postencepha-
litic parkinsonism had a few GFAs in the frontal cortex, 
caudate nucleus and putamen in addition to a larger 
number of  distinct astrocytic lesions having very fine tau-
positive granules (Figure  3E–H). Three of  four cases of 
myotonic dystrophy had a few GFAs in the frontal cortex, 
caudate nucleus and/or amygdala (Figure  3I,J). All cases 
of  myotonic dystrophy had characteristic tau-positive astro-
cytic lesions in which crinkly or twisted thread-like struc-
tures were distributed in the peripheral rather than the 
central portion (Figure  3K–O). One case with DNTC had 
a few GFAs in the putamen.
Frequency and distribution patterns of GFAs 
and TAs in AGD, PSP, AD and PART groups
AGD cases, PSP cases without AGD, AD cases without 
AGD and PART cases without AGD showed distinct 
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distribution patterns of  GFAs (Figure  4A–D). In AGD 
cases, GFAs were consistently noted in the amygdala 
(100.0%), followed by the putamen (69.2%) and caudate 
nucleus and frontal cortex (57.7%, respectively) and the 
high density of  GFAs of  stage 2 or over was frequently 
found in the amygdala (54.2%) rather than the frontal 
cortex, caudate nucleus and putamen (19.2%, 15.4% and 
11.5%, respectively) (Figure  4A). In PSP cases without 
AGD, in contrast to AGD cases, a large number of  GFAs 
were consistently noted in the amygdala, caudate nucleus 
and putamen (100.0%, respectively), and also frequently 
in the frontal cortex (90.0%) (Figure  4B), and the high 
density of  GFAs of  stage 2 or over was frequently found 
in the frontal cortex, caudate nucleus, putamen (80%, 70% 
and 70%, respectively) rather than the amygdala (33.3%) 
(Figure  4B). In AD cases without AGD, although far less 
frequent compared with AGD and PSP groups, GFAs were 
noted in the putamen (35.0%), followed by the caudate 
nucleus (30.0%), frontal cortex (20.0%) and amygdala (5.3%) 
(Figure  4C). In PART cases without AGD, GFAs were 
most frequently noted in the amygdala (35.3%), followed 
by the frontal cortex (16.7%) and the caudate nucleus and 
putamen (5.6%, respectively), being similar to the distribu-
tion pattern observed in AGD rather than AD cases 
(Figure  4D). The age at death, sex, brain weight, Braak 
stage, Thal phase, the proportion of  cases with Lewy body 
disease (LBD) and the proportion of  cases with TDP-43 
pathology were not significantly different between PART 
cases with and without GFAs (Mann–Whitney U test and 
Fisher’s exact test; Supporting File S1).
In AGD, PSP, AD and PART groups, the distribution 
pattern of GFAs was similar to those of AT8-positive TAs 
and Gallyas-positive TAs, respectively (Figure  4A–D).
In the comparison between AGD, PSP and AD groups, 
the densities of GFAs in the amygdala in an AGD group 
were significantly larger than those in the AD group, respec-
tively (P  <  0.001, Kruskal–Wallis and Steel–Dwass tests). 
The densities of GFAs in all regions in the PSP group 
were significantly larger than those in the AD group 
(P  <  0.001, respectively, Kruskal–Wallis and Steel–Dwass 
tests). The densities of GFAs in the frontal cortex, caudate 
nucleus and putamen in the PSP group were significantly 
larger than those in the AGD group (P  =  0.006, 0.007 and 
0.004, respectively, Kruskal–Wallis and Steel–Dwass tests).
Figure 2. GFAs and disease-specific astrocytic lesions in PSP, AD and 
CBD cases. A–E. GFAs in the amygdala (A, E), caudate nucleus (B, C) 
and putamen (D) in PSP cases. AT8 immunohistochemistry. F–J. Double 
immunohistochemistry for tau (AT8, blown) and Aβ (12B2, blue) of GFAs 
in AD cases. The frontal cortex. F–J. Most GFAs in AD cases did not 
overlap Aβ-positive plaques (F–H). In AD cases, GFAs were often 
associated with a few short thick dystrophic neurites that may originate 
from neurons (an arrow) (G) and had very fine powdery tau-positive 
granules. K–O. GFAs and astrocytic plaques in CBD cases. AT8 
immunohistochemistry. K, L. GFAs in a CBD case that could not be 
morphologically differentiated from those in AGD cases. The frontal 
cortex. M, N. Astrocytic plaque-like tau pathologies in a CBD case. Tau 
tends to be relatively predominantly accumulated in the distal portion of 
astrocytic processes. The frontal cortex. O. Typical astrocytic plaques in 
a CBD case. The frontal cortex. All scale bars = 30 μm. 
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According to recently proposed distribution patterns of 
ARTAG (44), the distributions of GFAs in AGD and PART 
cases were similar to pattern 1 (amygdala first pattern), while 
the distribution of GFAs in AD cases was similar to pattern 
2 (striatum first pattern), respectively (Supporting File S2).
Age at death and pathological features by 
region in all cases with or without GFAs
We then compared the age at death and pathological features 
of all cases with and without GFAs to explore factors 
potentially associated with GFA formation (Table  3). The 
age at death in cases having GFAs in the caudate nucleus 
and putamen was significantly higher than that in cases 
lacking GFAs, respectively (P  =  0.005 and <0.001, respec-
tively, Mann–Whitney U test; Table  3). The AGD stage in 
cases having GFAs in the caudate nucleus, putamen and 
amygdala was significantly higher than that in cases lacking 
GFAs (P  =  0.004, 0.002, and <0.001, respectively, Mann–
Whitney U test). The frequency of PSP cases was signifi-
cantly higher in cases having GFAs than in cases lacking 
GFAs in all regions, respectively (P  <  0.001, respectively, 
Fisher’s exact test). Braak stage, Thal phase and the fre-
quencies of LBD and TDP-43-positive lesions did not differ 
between the two groups.
Correlation analyses of GFA stage and clinical 
and pathological variables by region in all 
subjects
The correlations between the GFA stage and clinical and 
pathological variables in all subjects were analyzed using 
Spearman rank order correlations (Supporting File S3). The 
AGD stage was significantly correlated with the GFA stage 
Figure 3. GFAs and other distinctive tau-positive astrocytic lesions in 
cases of multiple system atrophy, dentatorubral-pallidoluysian atrophy, 
postencephalic parkinsonism and myotonic dystrophy. A, B. GFAs in 
an MSA case with PART but without any other primary tauopathy. 
AT8 immunohistochemistry. The amygdala. C, D. GFAs in a DRPLA 
case with PART but without any other primary tauopathy. AT8 
immunohistochemistry. The amygdala. E–H. Double immuno-
histochemistry for tau (AT8, brown) and Aβ (12B2, blue) of GFA-like 
astrocytic tau pathologies in a case of postencephalitic parkinsonism. 
Glial lesions that are composed of fine tau-positive granules are usually 
independent of Aβ deposits. The amygdala. I–O. GFAs and distinct tau-
positive astrocytic lesions in cases of myotonic dystrophy (MD). AT8 
immunohistochemistry. I–K. GFAs in an MD case. The amygdala. 
Some GFAs were in contact with vessel walls, in which tau was 
densely accumulated in astrocytic endfeet touching the vessel (K). L. 
Tau-positive astrocytic lesions having both twisted or crinkly thin 
threads and granular components like those observed in GFAs in an 
MD case. The frontal cortex. M, N. Tau-positive astrocytic lesions that 
include almost only twisted or crinkly thin threads in an MD case. The 
frontal cortex. O. Astrocytic lesions mainly composing of longer 
twisted tau-positive threads in addition to various quantities of fine 
tau-positive granules are often noted in an MD case. Twisted fine 
threads are often radially arranged, appearing to be reminiscent of 
threads in astrocytic plaques in CBD. However, the threads of 
astrocytic lesions in MD cases tend to be finer and longer than those 
usually observed in astrocytic plaques in CBD cases (see Figure 2O). 
The frontal cortex. All scale bars = 30 μm. 
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Figure 4. Distribution and density of AT8-positive GFAs, AT8-positive 
TAs and Gallyas-positive TAs in AGD, PSP, AD and PART groups. A. In 
AGD cases (N  =  26), GFAs and TAs show similar distributions: both 
lesions most frequently develop in the amygdala, and GFAs are more 
frequent that TAs in all regions examined. B. In PSP cases (N = 10), GFAs 
were almost consistently noted in all regions examined, and the 
proportions of cases having the high density GFAs (stage 2 or over) in 
the striatum and frontal cortex were higher than that in the amygdala. 
The distribution pattern of TAs was similar to that of GFAs. C. In AD 
cases (N = 20), GFAs were more frequent in the striatum compared with 
the frontal cortex and amygdala, although less frequent than in AGD and 
PSP cases. D. In PART cases (N = 18), GFAs were the most frequent in 
the amygdala, whose distribution pattern was similar to that in an AGD 
rather than AD and PSP groups. *Significant differences between PSP 
and AD groups (P < 0.01). †Significant differences between AGD and AD 
groups (P  <  0.01). ‡Significant differences between AGD and PSP 
groups (P < 0.01). Kruskal–Wallis and Steel–Dwass tests. 
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in the putamen and amygdala, respectively (ρ  =  0.271 and 
0.530; P  =  0.005 and <0.001). On the contrary, the age at 
death was significantly correlated with the GFA stage only 
in the caudate nucleus and putamen (ρ  =  0.267 and 0.358; 
P  =  0.006 and <0.001).
The GFA stages in the frontal cortex, caudate nucleus, 
putamen and amygdala were significantly correlated with 
the density of Gallyas-positive TAs in the same regions 
(ρ  =  0.647, 0.507, 0.534 and 0.332; P  <  0.001, respectively). 
Neither Braak stage nor Thal phase was significantly cor-
related with the GFA stage in any region.
Effects of age, Braak stage, Thal phase, PSP 
and AGD on GFA formation by region
Ordered logistic regression analyses were used to examine 
whether the age at death, Braak stage, Thal phase, presence 
or absence of PSP and presence or absence of AGD were 
independently associated with the increase of GFA stage 
by region in all cases (Table  4).
In the frontal cortex, the strongest independent factor 
of GFA formation was the pathological diagnosis of PSP 
(OR 214.19; 95% CI 29.16–1573.46), followed by the pres-
ence of AGD (OR 7.30; 95% CI 2.31–23.04). Likewise, in 
the caudate nucleus, PSP (OR 483.92; 95% CI 56.76–4125.91) 
was the strongest factor associated with GFA formation, 
followed by AGD (OR 14.68; 95% CI 3.69–58.41). In the 
putamen also, the strongest factor of GFA formation was 
PSP (OR 1020.11; 95% CI 96.4–10795.5), followed by AGD 
(OR 15.66; 95% CI 3.98–61.65).
In contrast, in the amygdala, the pathological diagnosis 
of AGD had the strongest association with GFA formation 
(OR 118.14; 95% CI 23.5–594.4), followed by PSP (OR 
52.95; 95% CI 9.3–300.9). The age at death, Braak stage 
or Thal phase was not significantly associated with GFA 
formation in any region examined.
Relationship between change of 
immunoreactivity of GFAs and TAs and 
progression of argyrophilic grains in AGD 
cases
Based on the significant correlation between the stages of 
GFAs and AGD in all regions demonstrated by univariate 
and multivariate analyses (Table  4 and Supporting File S3), 
to explore findings associated with the formation process 
of GFAs, the change of immunoreactivity of GFAs in the 
frontal cortex and putamen in AGD cases was examined 
using a panel of anti-tau, ubiquitin and p62 antibodies and 
the Gallyas method after stratification by AGD stage 
(Figure 5A,B). In this examination, astrocytic lesions having 
Gallyas-positive glial threads were regarded as TAs regard-
less of the quantity of argyrophilic structures. In both regions 
examined, with the progression of AGD stage, phosphoryla-
tion- and conformation-dependent anti-tau antibodies increas-
ingly labeled GFAs and TAs, respectively (Figure  5A,B). 
Gallyas-positive TAs were noted only in cases with AGD 
stages II or higher. p62-positive GFAs occurred only in 
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Double staining with AT8 
immunohistochemistry and Gallyas method
Double staining with AT8 immunohistochemistry and the 
Gallyas method demonstrated astrocytic lesions having fine 
GFA-like granular tau accumulation, and like TAs, a few 
to a moderate number of Gallyas-positive glial threads in 
AGD cases (Figure 6A–D). Some lesions had thicker Gallyas-
positive threads (Figure  6D), being indistinguishable from 
TAs in PSP cases (Figure  6F). Similar astrocytic lesions 
having both fine tau-positive granules and Gallyas-positive 
threads were noted in PSP cases also (Figure  6E).
Confocal laser scanning microscopy
In AGD cases, double labeling with AT8 and anti-4R tau 
antibodies showed the accumulation of 4R tau in GFAs 
(Figure  7A–F). Some TAs were intensely stained with anti-
4R tau antibody in AGD cases (Figure  7G–I). The accu-
mulation of p62 was revealed in AT8-positive GFAs and 
TAs with relatively thick glial threads (Figure  7J–O).
Tau immunoblotting in representative AGD  
and PSP cases
Immunoblot analysis of  the sarkosyl-insoluble, urea-soluble 
fraction prepared from the right hemisphere with T46 and 
pS396 demonstrated approximately 68- and 64-kDa bands 
in all AGD, PSP and CBD cases (Figure  8A, lanes 1–8 
and Figure 8B, lanes 10–17). All bands and smears tended 
to be more strongly stained with pS396 than T46. Low 
molecular weight tau fragments of  approximately 33- and 
37-kDa were also noted in PSP (lanes 4–7 and 13–16) 
and CBD (lanes 8 and 17), respectively. Of  two AGD 
cases, one case (AGD1) showed approximately 33- to 
37-kDa tau fragments in the putamen and caudate nucleus 
(lanes 1, 2, 10 and 11). The immunointensity of  the frag-
ments was less than those in PSP cases. The other AGD 
case (AGD2) showed very weakly stained 33- to 37-kDa 
tau fragments in the putamen (lanes 3 and 12). The den-
sity of  GFAs in corresponding regions in the left hemi-
sphere was comparable between these AGD and PSP cases 
(table of  Figure  8B). On the contrary, GFAs and TAs 
tended to be stained with a larger number of  anti-tau 
antibodies in PSP cases (lanes 13–15) than AGD cases 
(lanes 10–12). In these cases, GFAs and TAs stained with 
anti-p62 antibodies and/or Gallyas method were noted 
only in PSP cases (lanes 13–15).
DISCUSSION
This is the first study that demonstrated distinct distribu-
tions of GFAs in AGD, PSP, AD and PART cases and 
comprehensively evaluated the impacts of patient age and 
major pathological factors on GFA formation by anatomical 
region. In AGD cases, GFAs were consistently noted in the 
amygdala, and to a lesser frequency, in the striatum and 
frontal cortex (57–69%). In PSP cases, GFAs were almost 
consistently noted in all regions, and the proportion of 
cases having the high density of GFAs was higher in the 
striatum and frontal cortex than in the amygdala. In con-
trast, only 35% of AD cases showed a few GFAs in the 
striatum, followed by the frontal cortex (20%) and amygdala 
(5%). Although the PART cases lacked AGD or any other 
primary tauopathies, 35% had a few GFAs with a distribu-
tion more similar to that in AGD than in AD cases. In 
multivariate ordered logistic regression analyses, PSP was 
the strongest independent factor of GFA formation in the 
frontal cortex, caudate nucleus and putamen, while AGD 
was the strongest independent factor of GFA formation in 
the amygdala. In contrast, neither age nor AD pathology 
was significantly associated with GFA formation in any 
region examined. In AGD cases, GFAs labeled with phos-
phorylation- and conformation-dependent anti-tau antibodies, 
Gallyas-positive glial threads in GFAs and the activation 
of autophagy sequentially occurred parallel to the progres-
sion of AGD. These findings suggest that GFAs may develop 
with a distinct distribution pattern associated with underlying 
tauopathies rather than age.
Cases of primary tauopathies often had not only disease-
specific astrocytic lesions, but also not negligible numbers 
of morphologically unclassifiable tau-positive astrocytic lesions 
(39,43,44). Indeed, in our cases of PSP, CBD, myotonic 
dystrophy and postencephalitic parkinsonism, unclassifiable 
tau-positive astrocytic lesions having both morphological 
features of GFAs and disease-specific astrocytic lesions were 
Table 4. Ordered logistic regression analyses of associations between 
density of GFAs, age, Braak stage, Thal phase, PSP and AGD by 
anatomical region in all subjects
  Odds ratio 95% confidence interval P-value
GFAs in the frontal cortex
Age at death 1.03 0.98–1.08 0.325
Braak stage 1.27 0.90–1.79 0.171
Thal phase 0.87 0.63–1.20 0.391
PSP 214.19 29.16–1573.46 <0.001*
AGD 7.30 2.31–23.04 <0.001*
GFAs in the caudate nucleus
Age at death 1.02 0.96–1.07 0.582
Braak stage 1.54 1.02–2.32 0.038
Thal phase 1.07 0.77–1.49 0.686
PSP 483.92 56.76–4125.91 <0.001*
AGD 14.68 3.69–58.41 <0.001*
GFAs in the putamen
Age at death 1.07 1.01–1.13 0.022
Braak stage 1.67 1.10–2.54 0.015
Thal phase 0.84 0.60–1.17 0.293
PSP 1020.11 96.40–10795.50 <0.001*
AGD 15.66 3.98–61.65 <0.001*
GFAs in the amygdala
Age at death 1.00 0.95–1.06 0.947
Braak stage 1.14 0.81–1.61 0.454
Thal phase 0.73 0.51–1.05 0.093
PSP 52.95 9.32–300.92 <0.001*
AGD 118.14 23.48–594.39 <0.001*
*P < 0.01.
Abbreviations: AGD = the presence of AGD lacking any other primary 
tauopathies; GFA = granular/fuzzy astrocyte; PSP = the presence of PSP 
lacking any other primary tauopathies.
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observed. Therefore, it is considered that where the boundary 
in the morphological evaluation is set may affect the fre-
quency of GFAs in each study. In this study, to secure the 
reproducibility of results, only astrocytic lesions which showed 
morphological features of classic GFAs originally reported 
in AGD cases were regarded as GFAs (4). The previously 
reported higher frequency of GFAs in CBD cases (e.g., about 
90% in the frontal cortex and striatum in the CBD cases 
(44) vs. 14.3% in the sites in our CBD cases) may be at 
least partially explained by such methodological issues, it 
being difficult to simply compare the frequency of GFAs 
between studies.
Although there are several previous studies regarding the 
immunoreactivity of GFAs (17,45,60), the change of 
Figure 5. Changes of immunoreactivity of GFAs and TAs parallel the 
progression of the AGD stage in the frontal cortex (A) and putamen (B) 
in AGD cases. About 35% of cases with AGD stage I had GFAs labeled 
by several anti-tau antibodies in the frontal cortex and putamen. Neither 
Gallyas- nor p62-positive lesions were noted in these cases. Gallyas-
positive TAs were first noted in cases with AGD stage II, and the 
proportion of AGD cases with TAs increased with AGD stage. p62-
positive GFAs were first noted in cases with AGD stage III. In this study, 
when an astrocytic lesion had Gallyas-positive glial threads, we 
operationally regarded it as a TA irrespective of the quantity of Gallyas-
positive threads. 
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immunoreactivity related to the process of GFA formation 
is hardly known. In our study, because the AGD stage was 
significantly correlated with the density of GFAs (Table  4), 
we considered that the change of immunohistochemical 
features of GFAs associated with the progression of the 
AGD stage may reflect the formation process of GFAs, at 
least in AGD cases. We selected the frontal cortex and 
putamen as regions of interest for this examination because 
the number of GFAs in these sites varied between cases. 
As a result, it was demonstrated that the increase of GFAs 
labeled with phosphorylation- and conformation-dependent 
anti-tau antibodies and the activation of autophagy occurred 
in the regions parallel to the progression of AGD (Figure 5). 
It was also noteworthy that, with the increase of GFAs, 
Gallyas-positive glial threads indistinguishable from those 
observed in TAs in PSP cases gradually increased in GFAs 
in AGD cases (Figure  5), and that the distribution of TAs 
was consistent with that of GFAs (Figure  4). Further, 
Gallyas-AT8 double staining demonstrated that some GFAs 
in AGD cases actually had a few fine Gallyas-positive threads 
in addition to Gallyas-negative tau-positive fine granular 
structures as features of GFAs. Based on these findings, it 
is plausible that at least some GFAs may precede changes 
of full-blown Gallyas-positive TAs. On the contrary, at pre-
sent, TAs are considered to be disease-specific lesions of 
PSP. Therefore, regardless of the quantity, the presence of 
TAs is often regarded as an early change of PSP. In this 
study, Gallyas-positive TAs were observed in about 40% of 
AGD cases as well as all PSP cases. However, because the 
distribution pattern of TAs, like that of GFAs, evidently 
differs between PSP and AGD cases (Figure 4), we consider 
that whether a small number of Gallyas-positive TAs observed 
in AGD cases always means the coexisting early change of 
PSP remains to be elucidated. Interestingly, in our results 
of tau immunoblotting, although the number of cases exam-
ined was small, the band pattern of approximately 33- to 
37-kDa low-molecular weight tau fragments might differ 
between AGD and PSP cases even when the same anatomi-
cal region (ie, striatum) was examined (Figure  8). It is also 
unclear whether the inconsistency reflects distinct patho-
physiologies in AGD and PSP, respectively, or reflects a 
continuum of GFAs and TAs that is shared by two tauopa-
thies. Further comparative studies between immunohisto-
chemical and biochemical findings using a larger number 
of cases are necessary to clarify the pathogenic significances 
of GFAs and TAs in tauopathies, especially in AGD and 
PSP.
Kovacs et al (44) statistically explored potential progres-
sion patterns of ARTAG in a large case series including 
cases of CBD, PSP, Pick’s disease, PART, AD, MSA, LBD 
and ALS. AGD coexisted in some cases, although detailed 
information, for example, the number of cases having AGD 
and the severity of AGD, was not shown. In their study, 
they statistically extracted two potential progression patterns 
of GFAs, that is, patterns 1 and 2 (44). In pattern 1, GFAs 
may first develop in the striatum and extend to the fron-
totemporal cortex [the striatum first pattern (37)]. 
Interestingly, this pattern appears to be consistent with that 
of GFAs observed in our AD cases (Figure 4C). Considering 
that Kovacs’s 528 non-FTLD tauopathy cases included 243 
AD cases (46.0%), it is plausible that pattern 1 mainly 
reflects the distribution of GFAs in their AD cases. Regarding 
the distribution of GFAs in AD cases, a recent study exam-
ined the frequency of GFAs in the frontal, temporal, cin-
gulate, angular gyri, putamen, amygdala and entorhinal 
cortex (59). Although GFAs were comparable in density in 
these regions, in their study, unlike ours, AD cases with 
AGD were not excluded because of their high frequency. 
However, given our findings, such a selection might increase 
the frequency of GFAs in the amygdala in AD cases. In 
addition, multivariate analyses demonstrated that AGD was 
not associated with the presence of GFAs, being inconsist-
ent with our results. However, the effect of AGD on GFA 
formation was not evaluated by anatomical region. Therefore, 
their findings cannot be compared with our results. On the 
Figure 6. Double staining with AT8 immunohistochemistry and Gallyas 
method of tau-positive astrocytic lesions in AGD and PSP cases. A, B. 
Some GFA-like astrocytic lesions having various quantities of fine 
granular tau accumulation and a few Gallyas-positive threads in an AGD 
case. The frontal cortex. C, D. TAs having Gallyas-positive threads in 
AGD cases. The frontal cortex. E, F. GFA-like astrocytic lesion (E) and TA 
(F) having various quantities of tau-positive granules and Gallyas-positive 
threads in PSP cases. The putamen. All scale bars = 30 μm. 
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Figure 7. Confocal double-immunofluorescence of the combination of 
AT8 (A, D, G) and anti-4R tau antibodies (B, E, H), and the combination 
of AT8 (J, M) and p62-C (K, N) in the frontal cortex in an AGD case. A–C, 
D–F. GFAs. An AT8 epitope is partially colocalized with an anti-4R tau 
epitope. G–I. A TA. An anti-4R tau epitope is often colocalized with an 
AT8 epitope. J–L. A GFA. Some GFAs having not only fine tau granules, 
but also coarse tau granules showed the colocalization of epitopes of 
AT8 and p62-C. M–O. A TA. Some TAs also rarely showed the 
colocalization of epitopes of AT8 and p62-C. C, F, I, L, O. Merged 
images. All scale bars = 20 μm. 
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contrary, in pattern 2 reported by Kovacs et al (44), GFAs 
may first develop in the amygdala and subsequently in the 
subcortical nuclei and frontotemporal cortex [the amygdala 
first pattern (37)], being consistent with the distribution 
pattern of GFAs observed in our AGD cases (Figure  4A). 
Somewhat unexpectedly, previously reported findings regard-
ing the detailed distribution and frequency of GFAs in 
AGD cases are limited. In a previous study including 54 
cases of degenerative diseases with coexisting AGD, it was 
demonstrated that GFAs were most frequent in the medial 
temporal region including the hippocampus, amygdala and 
inferior temporal gyrus, and the proportion of cases having 
GFAs at least in one of these regions was 90.4% (43). In 
that study, only three cases of AGD without any other 
primary tauopathy were examined; of these, one case had 
GFAs at least in one of the regions, although the detailed 
distribution was not described. In another study, only the 
effect of grains as coexisting lesions in the hippocampus 
pyramidal layers, dentate gyrus, inferior temporal gyrus and/
or amygdala on GFA formation in the amygdala in a case 
series of diverse degenerative diseases was examined, and 
a significant relationship between grains in these regions 
and GFAs in the amygdala was noted (44). Based on these 
previous findings together with our results, when GFAs are 
predominantly distributed in the amygdala, the possibility 
should be considered that the case may have the pathogenic 
process associated with the formation of argyrophilic grains.
It is noteworthy that about 35% of our PART cases had 
GFAs, the distribution of which was consistent with that 
in AGD cases, although they lacked argyrophilic grains. In 
a previously reported series of PART cases as well, a similar 
distribution pattern of GFAs with the highest frequency in 
the amygdala (29%) was observed (44). These results led 
us to consider the possibility that at least some PART cases 
with amygdala-predominant GFAs actually have not only 
the pathological process of PART, but also the very early 
glial change of AGD, even when lacking argyrophilic grains 
on sections stained with the Gallyas method. This view 
may be supported by previous statistical analyses using the 
conditional probability that demonstrated that GFA 
Figure 8. Tau immunoblot analysis of the sarkosyl-insoluble, urea-
soluble fraction prepared from the right hemisphere of representative 
AGD (AGD1 and AGD2), PSP (PSP1 and PSP2) and disease control 
cases (PSP3, CBD and AD) with T46 (A) and pS396 (B). All bands and 
smears tended to be more strongly stained with pS396 rather than T46. 
Approximately 68- and 64-kDa bands are seen in all AGD (lanes 1–3, 
10–12), PSP (lanes 4–7, 13–16) and CBD cases (lanes 8 and 17). Cases of 
PSP (lanes 4–6, 13–15) and CBD (lanes 8 and 17) show 33- and 37-kDa 
mass tau fragments, respectively. One of two AGD cases showed less 
intensely stained 33- to 37-kDa tau fragments in the putamen and 
caudate nucleus (lanes 1, 2, 10 and 11). In the other AGD case, the 
immunoreactivity of 33- to 37-kDa tau fragments in the putamen was 
very weak (lanes 3 and 12). On tau immunohistochemistry in 
corresponding regions of the left hemisphere, the density of GFAs were 
comparable between AGD and PSP cases (Table of Figure 8B). However, 
TAs tended to be stained with a larger number of anti-tau antibodies in 
PSP cases than AGD cases. Further, in these cases, GFAs and TAs 
stained with anti-p62 antibodies and/or Gallyas method were noted only 
in PSP cases. Abbreviations: AGD  =  argyrophilic grain disease; 
AD = Alzheimer’s disease; Caud = caudate nucleus; CBD = corticobasal 
degeneration; F = frontal cortex; PSP = progressive supranuclear palsy; 
Put = putamen; n.e. = Gallyas-positive GFAs were not evaluated in PSP 
cases because many Gallyas-positive dot-like structures were scattered, 
and thereby made it difficult to count Gallyas-positive GFAs; T = temporal 
cortex.
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formation may precede grain formation in the amygdala 
(44). The distribution pattern of GFAs was evidently dif-
ferent between our AD and PART cases, suggesting that 
the tau accumulation in astrocytes observed in PART cases 
may not be an early process of GFA formation in AD. 
Further, considering that GFAs in the amygdala were rare 
even in AD cases with a high Braak NFT stage (V–VI), 
it is unlikely that amygdala GFAs with high frequency in 
PART cases developed in association with PART with a 
lower Braak NFT stage (I–IV). On the contrary, our results 
also appear to suggest that the presence or absence of GFAs 
in the amygdala may be related to the progression from 
PART to full-blown AD pathology. Considering that extensive 
tau accumulation in the neocortex may require sufficient 
cortical Aβ accumulation in AD cases (65) and the possibil-
ity that amygdala GFAs may be associated with argyrophilic 
grains (44), the potential relationship can be at least partially 
explained by the poverty of Aβ deposits and a related genetic 
background in AGD cases. For example, it has been reported 
that the frequency of the ApoE ε4 allele in AGD cases 
was significantly lower than that in AD cases (73), the 
frequency of the ApoE ε2 allele in AGD cases was signifi-
cantly higher than that in normal controls (19) and the 
neocortical Aβ load in AGD cases was significantly lower 
than that in AD cases (70,72). These findings may be con-
sistent with the relationship between the lack of amygdala 
GFAs and the evolution from PART to AD observed in 
our study. Given these findings, it is plausible that the 
pathogenic background in PART cases may be heterogene-
ous, and a genetic background associated with amygdala 
GFAs should be explored.
Limitations of  this study have to be considered. First, 
a significant factor affecting the results is the small number 
of  cases, especially those of  PSP and other rare tauopa-
thies and non-tauopathies, although a P-value <0.01 was 
accepted as significant to interpret the results with caution. 
Second, in our semiquantitative assessment, to strictly set 
the morphological criteria of  GFAs, we counted lesions 
as GFAs only when they showed the morphological fea-
tures of  GFAs common in the AGD cases reported origi-
nally by Botez et al (4). In the consensus paper also, the 
astrocytic lesions observed in AGD brains are regarded 
as most typical for GFAs (38). The narrow definition of 
GFAs used in this study might reduce the frequency of 
lesions. However, considering that the characteristic dis-
tribution patterns of  GFAs were revealed in several diseases 
using such an evaluation procedure, focusing on GFAs 
showing morphological features commonly observed in 
AGD brains might be rather useful to explore the patho-
logical process in tauopathies. In this context, the patho-
logical relationship between GFAs and thorn-shaped 
astrocytes might be also needed to be examined. Third, 
we presented results of  tau immunoblotting using tissues 
from the right hemisphere with findings of  immunoreac-
tivity and argyrophilia of  GFAs and TAs in corresponding 
regions in the left hemisphere in each case. However, the 
possibility that there might be a discrepancy between the 
hemispheres regarding tau pathology cannot be denied. 
Therefore, tau immunohistochemistry and immunoblotting 
using tissue from the ipsilateral hemisphere in a larger 
number of  AGD cases might provide more suggestive 
findings to address these issues.
In conclusion, we demonstrated that the development of 
GFAs may be distinctively affected by underlying pathologi-
cal bases by region rather than age; therefore, GFAs showed 
characteristic distribution patterns associated with underlying 
tauopathies. Whether evaluating the distribution of GFAs 
is useful to predict underlying tauopathies, especially in the 
early phase of the pathological process in some diseases, 
should be further examined. In addition, the potential impact 
of GFAs on motor and cognitive functions and the psy-
chiatric condition of people with and without neurological 
diseases may be of clinical interest and should be explored 
in the future.
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